Observational study / 2011
A new post-epidemic case of eosinophilia-myalgia syndrome was reported in association with L-tryptophan consumption.
This case report describes a new case of eosinophilia-myalgia syndrome (EMS) associated with L-tryptophan following the lifting of the FDA ban in 2005. The report details clinical, histopathologic, and immunogenetic features of the patient. In addition, evidence of activated transforming growth factor β and interleukin-4 signaling was identified in the lesional skin.
Shows an association, not proof of cause and effect.
- Study type
- Case report
- Who was studied
- A patient with L-tryptophan-associated eosinophilia-myalgia syndrome
- What was measured
- Clinical, histopathologic, and immunogenetic features
THE PAPER
Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.
Allen JA, Peterson A, Sufit R, Hinchcliff ME, Mahoney JM, Wood TA, Miller FW, Whitfield ML, Varga J. Arthritis Rheum, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.